Drug Trial Radar · NCT07344779
A Study to Learn How Men With Advanced Prostate Cancer Respond to Treatment With Darolutamide and Hormone Therapy, With or Without Chemotherapy, in Real-world Medical Practice
Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,600
Planned (sponsor's estimate)
Start
Jan 29, 2026
Primary completion
Dec 31, 2029
Study completion Jun 30, 2030
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- Jan 15, 2026
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an international, prospective, open-label, multicenter, multi-cohort, non-interventional observational study designed to describe the real-world effectiveness and safety of darolutamide in combination with androgen deprivation therapy (ADT), with or without docetaxel, in patients with metastatic hormone-sensitive prostate cancer (mHSPC). The study aims to enroll approximately 1,600 male patients (800 per cohort) from multiple countries, primarily in Europe, who have a diagnosis of mHSPC and for whom a decision to treat with darolutamide has been made by the treating physician prior to enrollment. The primary objective is to estimate the proportion of patients achieving undetectable prostate-specific antigen (PSA) levels (\<0.2 ng/mL) at 1 year of treatment in each cohort. Secondary objectives include describing patient demographics, clinical characteristics, prior and concomitant treatments, adverse events, and clinical effectiveness measures such as overall survival, time to new treatment, time to castration resistance, and time to PSA progression. Further objectives involve assessing quality of life, reasons for not adding docetaxel, outcomes by patient subgroups (e.g., Gleason score, disease volume, ECOG status), genomic testing results, and hospitalization rates. Data will be collected using electronic case report forms (eCRF) during routine clinical practice, with no additional diagnostic or monitoring procedures required beyond standard care. All patients must provide informed consent prior to participation. The study will comply with applicable regulatory requirements, including IEC/IRB approval in all participating countries. Statistical analyses will be descriptive and exploratory, with interim analyses planned after 200, 400, and 600 patients per cohort have completed at least 12 months of treatment or discontinued therapy. The study is expected to provide valuable insights into the real-world use of darolutamide in mHSPC, supporting clinical decision-making and enhancing understanding of treatment patterns, effectiveness, and safety in diverse patient populations.
Conditions
- Metastatic Hormone-Sensitive Prostate Cancer
Interventions
Darolutamide (BAY 1841788)Drug
Darolutamide administered per local standard of care in combination with ADT.
ADTDrug
Androgen deprivation therapy administered per local standard of care.
DocetaxelDrug
Docetaxel administered per local standard of care in combination with darolutamide and ADT for cohort 1.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of patients in cohort 1 achieving undetectable PSA (<0.2 ng/mL) at 1 yearTime frame: after 1 year of treatment
- Proportion of patients in cohort 2 achieving undetectable PSA (<0.2 ng/mL) at 1 yearTime frame: after 1 year of treatment
Locations
16 sites in 16 countries. Site status is shown where the registry gives one.
Many Locations
Many Locations, Belgium · Recruiting
Many Locations
Many Locations, Finland · Recruiting
Many Locations
Many Locations, France · Recruiting
Many Locations
Many Locations, Germany · Not yet recruiting
Many Locations
Many Locations, Greece · Recruiting
Many Locations
Many Locations, Israel · Recruiting
Many Locations
Many Locations, Italy · Recruiting
Many Locations
Many Locations, Lithuania · Not yet recruiting
Many Locations
Many Locations, Norway · Not yet recruiting
Many Locations
Many Locations, Poland · Recruiting
Many Locations
Many Locations, Portugal · Not yet recruiting
Many Locations
Many Locations, Saudi Arabia · Not yet recruiting
Many Locations
Many Locations, Spain · Recruiting
Many Locations
Many Locations, Sweden · Not yet recruiting
Many Locations
Many Locations, Switzerland · Recruiting
Many Locations
Many Locations, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.